1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
ORGANIZATION
Pharma Labor Group Makes Direct Plea to Lawmakers against Off-Year Price Cuts
A group of pharma labor unions held an emergency gathering at a Diet building on April 2, leaning on dozens of legislators both from ruling and opposition parties to scrap “off-year” drug price revisions. Speaking to 41 Diet members, a…
To read the full story
Related Article
- Pharma Labor Group Renews Call for Abolition of Off-year Revisions
October 9, 2024
- Labor Union Group Urges Abolishment of Off-Year Price Revisions
June 27, 2024
- Japan Health Minister Hints Positive Stance on Off-Year Price Revisions
April 3, 2024
- Japan Needs New Rule to Price Drugs on Par with US, Europe: JPMA Director
October 27, 2023
ORGANIZATION
- Create NDA Category Modeled after FDA’s “505(b)(2)” Pathway: JEMA
February 20, 2025
- Generic Rate Tops 80% in All Prefectures for 1st Time in September: Payer
February 14, 2025
- US Lobbies Send Letters of Protest to Japan Embassy over Off-Year Revision, CEA
February 10, 2025
- Include Single IRB Policy in GCP to Accelerate Trials: EFPIA Official
February 10, 2025
- Role of IP Division Shifting to Partner Hunt and Dealmaking: JPMA Official
February 5, 2025
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…